Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Manaka

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
ESMO Open|March 21, 2021
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7T Takahashi, K Yamazaki, E Oki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trialK Yamazaki, T Yamanaka, M Shiozawa, et al.
ESMO Open|September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16H Yasui, Y Okita, M Nakamura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2021
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathyM Kanai, T Kawaguchi, M Kotaka, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
ESMO Open|March 21, 2021
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7T Takahashi, K Yamazaki, E Oki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trialK Yamazaki, T Yamanaka, M Shiozawa, et al.
ESMO Open|September 13, 2023
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16H Yasui, Y Okita, M Nakamura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2021
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathyM Kanai, T Kawaguchi, M Kotaka, et al.
Pageof 2